Epcoritamab,rituximab,cyclophosphamide,doxorubicin,vincristine,prednisone,lenalidomide,bendamustine,cytarabine,dexamethasone,oxaliplatin,carboplatin,gemcitabine,ifosfamide
genmab,abbvie
['epco ', 'nhl', 'lymsm', 'epcore,nhl,2', 'dlbcl', 'epcore,nhl,3', 'epcore,nhl,1', 'epcore,nhl,i,(-ii)']
epcore nhl-2
epco-rchop in high risk dlbcl with 1 y epco maintenance. 47 pts mfu 14.2 mo
51% g4 neutropenia, 13% fn
crs 60% g3 2%
cmr 80% orr 100%
responses seem durable although f/u too early. randomized data needed. #17icml #lymsm 
Clinician-researcher-educator @MSKCancerCenter Tweets about #Lymphoma #CLL #GeriOnc #PRO #MedEd Proud alum @OfficialJipmer @AIIMS_ND @UpstateNews @RoswellPark